



2026

PROSTATE CANCER FOUNDATION

SCIENTIFIC RETREAT

Thirty-Third Annual

October 2–4, 2026

Omni La Costa Resort · Carlsbad, California

Curing Together™

DAY ONE

Friday

October 2, 2026

AT A GLANCE

General Sessions · Costa Del Sol Ballroom

8:00 AM	Registration Costa Del Sol Foyer
1:00 PM - 1:05 PM	Welcome & Opening Remarks
1:05 PM - 1:25 PM	Panel: A Conversation with Patients
1:25 PM - 2:55 PM	Session 1: Advances in Cancer Immunotherapy: Distinguished Lecture and Session
2:55 PM - 3:20 PM	Special Lecture Stephen Squinto, PhD
3:20 PM - 4:25 PM	Session 2: Cancer Research Models: Which are Useful and How they can be Used
4:25 PM - 5:50 PM	Session 3: Multi-Omic Features of Prostate Cancer
5:50 PM - 6:10 PM	Special Lecture Charles Link, MD
6:15 PM - 7:00 PM	Dinner Costa Del Sol Patio
7:00 PM - 10:00 PM	Poster Session and Dessert Costa De La Luna Ballroom

LOCATIONS

Costa Del Sol Ballroom

General Sessions & Sponsored Presentations

Costa Del Sol Patio

Breakfast, Lunch & Friday Dinner

Costa Del Sol Foyer

Registration & Group Photo

Costa De La Luna Ballroom

Poster Session & Dessert

8:00 AM	Registration	Costa Del Sol Foyer
1:00 PM - 1:05 PM	Welcome & Opening Remarks Andrea Miyahira, PhD · Prostate Cancer Foundation Phillip Koo, MD · Prostate Cancer Foundation	
1:05 PM - 1:25 PM	Panel: A Conversation with Patients Phillip Koo, MD · Prostate Cancer Foundation Ron Woods · TBD	

SESSION 1

Advances in Cancer Immunotherapy: Distinguished Lecture and Session

Moderator: Andrea Miyahira, PhD | Prostate Cancer Foundation

1:25 PM - 2:55 PM

DISTINGUISHED LECTURE

1:25 PM - 1:50 PM

The James Allison Distinguished Lecture on Advances in Cancer Immunotherapy
The Past, Present, and Future for Checkpoint Immunotherapy in Solid Tumors
James Allison, PhD
University of Texas MD Anderson Cancer Center
Introduced by Charles Drake, MD, PhD | Johnson & Johnson Innovative Medicine
1:50 PM - 1:55 PM Discussion



SPEAKER BIOGRAPHY
Jim Allison, 2018 Nobel Laureate in Physiology or Medicine, pioneered immune checkpoint blockade as a cancer therapy. His lab showed that CTLA-4 inhibits T cell activation and that blocking it enables the immune system to reject tumors—work that established a new field and led to ipilimumab, the first FDA-approved checkpoint inhibitor. His current research aims to improve existing checkpoint therapies and identify new immune targets against cancer. He is Regental Professor and Chair of Immunology at MD Anderson Cancer Center and Founding Director of the James P. Allison Institute. A member of the National Academies of Sciences and Medicine; his honors include the Breakthrough Prize, the Lasker-DeBaakey Award, and the Balzan Prize.

1:55 PM - 2:10 PM

Myeloid-Driven Immunotherapy Resistance in Prostate Cancer Progression
Aram Lyu, PhD · Fred Hutchinson Cancer Center

2:10 PM - 2:15 PM

Discussion

2:15 PM - 2:30 PM

Activating Innate Immunity to Drive Tumor Control in Prostate Cancer
Akash Patnaik, MD, PhD · University of Chicago

2:30 PM - 2:35 PM

Discussion

2:35 PM - 2:50 PM

Investigating Xaluritamig + Abiraterone in Chemotherapy-Naïve Metastatic APMR Prostate Cancer
Tanya Dorff, MD · City of Hope

2:50 PM - 2:55 PM

Discussion

SPECIAL LECTURE

2:55 PM - 3:15 PM

Important Trends in Biotech Investing 2026
Stephen Squinto, PhD
J.P. Morgan Life Sciences Private Capital
Introduced by Phillip Koo, MD | Prostate Cancer Foundation
3:15 PM - 3:20 PM Discussion



SPEAKER BIOGRAPHY
Stephen Squinto, PhD, is CIO of J.P. Morgan Life Science Private Capital. Stephen brings 35 years of experience in biotechnology and drug development. He was an early company builder of Regeneron Pharmaceuticals, co-founder of Alexion Pharmaceuticals, and investor at OrbiMed Advisors. At Alexion, Stephen helped drive the discovery, development, regulatory approval, and global launch of transformative therapies for rare diseases. At OrbiMed, Stephen served on 20 company boards, co-founded several OrbiMed-backed companies, and acted as an operating executive for five.

SESSION 2

3:20 PM - 4:25 PM

Cancer Research Models: Which are Useful and How they Can be Used

Moderators: Cory Abate-Shen, PhD | Columbia University Medical Center; Yu Chen, MD, PhD | Memorial Sloan Kettering Cancer Center

- 3:20 PM - 3:30 PM

Genetically Engineered Mouse Models for Studying Prostate Cancer: When, Why, and How
Cory Abate-Shen, PhD · Columbia University Medical Center
- 3:30 PM - 3:40 PM

Immunocompetent Allograft Models & Lineage Plasticity
Rodrigo Romero, PhD · University of Texas MD Anderson Cancer Center
- 3:40 PM - 3:50 PM

From Bench to Bone: Innovative PDX Platforms for Prostate Cancer Metastasis
Estefania Labanca, PhD · University of Texas MD Anderson Cancer Center
- 3:50 PM - 4:00 PM

Employing Prostate Cancer Organoid Models to Understand Lineage States and Dependencies
Yu Chen, MD, PhD · Memorial Sloan Kettering Cancer Center
- 4:00 PM - 4:25 PM

Panel Discussion

SESSION 3

4:25 PM - 5:50 PM

Multi-Omic Features of Prostate Cancer

Moderator: Vanessa Hayes, PhD | University of Sydney

- 4:25 PM - 4:30 PM

Introduction
- 4:30 PM - 4:45 PM

The Geo-Ancestral Prostate Cancer Genome Consortium (GAP.CGC) - Unraveling Health Disparities
Vanessa Hayes, PhD · University of Sydney
- 4:45 PM - 4:50 PM

Discussion
- 4:50 PM - 5:05 PM

Genomic Determinants of Lethality and Therapeutic Vulnerability in Castration-Resistant Prostate Cancer
Marcin Cieslik, PhD · University of Michigan
- 5:05 PM - 5:10 PM

Discussion
- 5:10 PM - 5:25 PM

Evolution of AR Genetics During Prostate Cancer Progression
Scott Dehm, PhD · University of Minnesota
- 5:25 PM - 5:30 PM

Discussion
- 5:30 PM - 5:45 PM

Genomic Classification to Predict Survival in Metastatic Prostate Cancer: Development of Somatic Tumor Risk Assessment for Overall Survival-Prostate (STRATOS-P)
Martin Schoen, MD · St. Louis Veterans Affairs Medical Center; Saint Louis University
- 5:45 PM - 5:50 PM

Discussion

SPECIAL LECTURE

5:50 PM - 6:05 PM

Effective Resolution of Bone Metastases in Subjects with Metastatic Prostate Cancer Using SYNC-T SV102 Therapy

Charles Link, MD

Syncromune

Introduced by Andrea Miyahira, PhD | Prostate Cancer Foundation

6:05 PM - 6:10 PM Discussion



SPEAKER BIOGRAPHY COMING SOON

6:15 PM - 7:00 PM

Dinner

Costa Del Sol Patio

7:00 PM - 10:00 PM

Poster Session and Dessert

Costa De La Luna Ballroom

DAY TWO

Saturday

October 3, 2026

AT A GLANCE

General Sessions · Costa Del Sol Ballroom

7:00 AM - 7:45 AM	Breakfast Costa Del Sol Patio & Costa Del Sol Ballroom
7:15 AM - 8:00 AM	Sponsored Breakfast Presentation Bayer
8:00 AM - 8:25 AM	Special Lecture Himisha Beltran, MD
8:25 AM - 9:25 AM	Session 4: Metabolism & the Mechanisms of Treatment Resistance
9:25 AM - 9:50 AM	Dr. Felix Feng Legacy Lecture Joshua Lang, MD
9:50 AM - 10:10 AM	PCF Women in Science Lifetime Achievement Award Lecture Mary-Ellen Taplin, MD
10:10 AM - 10:45 AM	CEO's Address Gina Carithers, President & CEO
10:45 AM - 12:00 PM	Keynote Address Mike Milken, Founder and Chairman
12:00 PM - 12:15 PM	Group Photo Costa Del Sol Foyer
12:15 PM - 1:15 PM	Lunch Costa Del Sol Patio & Costa Del Sol Ballroom
12:30 PM - 1:00 PM	Sponsored Lunch Presentation Johnson & Johnson Innovative Medicine
1:30 PM - 2:40 PM	Session 5: Bench-to-Bedside New Drugs & New Targets
2:40 PM - 3:00 PM	Special Lecture Paul VanVeldhuisen, PhD
3:00 PM - 4:10 PM	Session 6: Lessons and Next Steps in the Neoadjuvant Space
4:10 PM - 5:00 PM	Panel Discussion: New Endpoints and Implications for Prostate Cancer Clinical Trials
5:00 PM - 6:30 PM	Break
6:30 PM - 7:00 PM	Reception Costa Del Sol Foyer
7:00 PM - 9:30 PM	Dinner & Awards Ceremony Costa Del Sol Ballroom

LOCATIONS

Costa Del Sol Ballroom

General Sessions & Sponsored Presentations

Costa Del Sol Patio

Breakfast, Lunch & Friday Dinner

Costa Del Sol Foyer

Registration & Group Photo

Costa De La Luna Ballroom

Poster Session & Dessert

7:00 AM - 7:45 AM

Breakfast

Costa Del Sol Patio & Costa Del Sol Ballroom

SPONSORED BREAKFAST PRESENTATION · COSTA DEL SOL BALLROOM

7:15 AM - 8:00 AM

Clinical Implications of Nutrition and Physical Activity in Advanced Prostate Cancer

Speaker TBD · Bayer

SPECIAL LECTURE

8:00 AM - 8:20 AM

Academic-Industry Partnership Models

Himisha Beltran, MD

Dana-Farber Cancer Institute

Introduced by Andrea Miyahira, PhD | Prostate Cancer Foundation

8:20 AM - 8:25 AM Discussion



SPEAKER BIOGRAPHY

Himisha Beltran, MD is a medical oncologist at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. She serves as Director of Translational Research in Medical Oncology at Dana-Farber and Co-Director of the Dana-Farber Center for Cancer Genomics. Her clinical and laboratory-based research have focused on developing therapeutic targets and biomarkers in castration resistant prostate cancer. She has had a particular emphasis on understanding non-androgen receptor driven prostate cancer including neuroendocrine prostate cancer, an aggressive subtype of castration resistant prostate cancer.

SESSION 4

8:25 AM - 9:25 AM

Metabolism & the Mechanisms of Treatment Resistance

Moderator: Nima Sharifi, MD | University of Miami

8:25 AM - 8:40 AM

Novel Combination Strategies to Enhance B7-H3–Targeted Therapies in Advanced Prostate Cancer

Di Zhao, PhD · University of Texas MD Anderson Cancer Center

8:40 AM - 8:45 AM

Discussion

8:45 AM - 9:00 AM

The Relationship between RB1 Loss and Tumor Metabolism

Dan Frigo, PhD · University of Texas MD Anderson Cancer Center

9:00 AM - 9:05 AM

Discussion

9:05 AM - 9:20 AM

How to Use Metabolism to Switch between Androgen and Glucocorticoid Programs

Nima Sharifi, MD · University of Miami

9:20 AM - 9:25 AM

Discussion

DR. FELIX FENG LEGACY LECTURE

9:25 AM - 9:45 AM

50 Lessons in Life, Leadership, and Science that Matters

Joshua Lang, MD

University of Wisconsin

Introduced by Mary Feng, MD | University of California, San Francisco

9:45 AM - 9:50 AM Discussion



SPEAKER BIOGRAPHY

Joshua Lang, MD, is a medical oncologist and Professor at the University of Wisconsin Carbone Cancer Center. He serves as the Associate Director of Translational Research, Director of the Circulating Biomarker Core, and Director of the Physician Scientist Training Program. He serves as a representative on the NCCN Prostate Cancer Guidelines committee. His laboratory is focused on defining resistance biology in advanced prostate cancer for novel diagnostic and therapy development. His laboratory and clinical research programs are funded by the Prostate Cancer Foundation, NIH, and many others.

PCF WOMEN IN SCIENCE LIFETIME ACHIEVEMENT AWARD LECTURE

9:50 AM - 10:05 AM

Following the Questions: A Career in Prostate Cancer Research

Mary-Ellen Taplin, MD

Dana-Farber Cancer Institute; Harvard Medical School

Introduced by Andrea Miyahira, PhD | Prostate Cancer Foundation

10:05 AM - 10:10 AM Discussion



SPEAKER BIOGRAPHY

Dr. Mary-Ellen Taplin is a Professor of Medicine at Dana-Farber Cancer Institute and Harvard Medical School and Chair of Dana-Farber's Executive Committee for Clinical Research. A genitourinary oncologist, she leads clinical trials of novel prostate cancer therapies, with a focus on androgen receptor signaling in high-risk localized and castration-resistant disease. She was principal investigator of the phase 3 PROTEUS trial, presented at the 2026 ASCO plenary and published in the New England Journal of Medicine, which showed that peri-operative androgen deprivation therapy plus apalutamide reduced the risk of metastasis by 20% in high-risk localized prostate cancer and is poised to change the standard of care.

In 2026 she received the UMass Chan Medical School Alumni Distinguished Service Award and the Prostate Cancer Foundation Women in Science Lifetime Achievement Award.

CEO'S ADDRESS

10:10 AM - 10:40 AM

Gina Carithers, President & CEO

Prostate Cancer Foundation

Introduced by Introducer TBD | Prostate Cancer Foundation

10:40 AM - 10:45 AM Discussion



SPEAKER BIOGRAPHY

Gina B. Carithers is an internationally recognized leader in healthcare marketing, communications, and business development. She was appointed President and CEO of the Prostate Cancer Foundation in 2024 after serving as its executive vice president and chief communications officer, a role she took on in 2022 when PCF acquired Digital Science Press and its flagship platform, UroToday.com. As DSP's founder and CEO, she built UroToday into a global resource serving three million urologists, oncologists, and patients around the world. Earlier, she spent 20 years at DuPont Pharmaceuticals, rising to executive vice president of its global virology franchise. She holds a B.A. from the University of California, Berkeley.

KEYNOTE ADDRESS

10:45 AM - 12:00 PM

Michael Milken, Founder and Chairman

Prostate Cancer Foundation

Introduced by Stuart Holden, MD | Prostate Cancer Foundation



SPEAKER BIOGRAPHY

Mike Milken has spent more than five decades at the forefront of medical research, education, public health, and access to capital. In 1993 he founded the Prostate Cancer Foundation to accelerate research into a disease that was then underfunded and overlooked. Built on a model of fast, competitive funding with minimal bureaucracy, PCF has raised more than \$1 billion and supported more than 2,600 research projects in 29 countries, making it the world's largest philanthropic funder of prostate cancer research. Mike also co-founded the Milken Family Foundation, chairs the Milken Institute and FasterCures, and co-launched the Melanoma Research Alliance. Fortune called him "The Man Who Changed Medicine."

12:00 PM - 12:15 PM Group Photo

Costa Del Sol Foyer

12:15 PM - 1:15 PM Lunch

Costa Del Sol Patio & Costa Del Sol Ballroom

SPONSORED LUNCH PRESENTATION · COSTA DEL SOL BALLROOM

12:30 PM - 1:00 PM

How to Develop a T Cell Engager

Charles Drake, MD, PhD · Johnson & Johnson Innovative Medicine

1:15 PM - 1:30 PM Move to Session

Costa Del Sol Ballroom

SESSION 5

1:30 PM - 2:40 PM

Bench-to-Bedside New Drugs & New Targets

Moderator: Elizabeth Wasmuth, PhD · UT Health San Antonio; Howard Hughes Medical Institute

1:30 PM - 1:35 PM

Introduction**DISTINGUISHED LECTURE**

1:35 PM - 1:55 PM

**Charles Sawyers Distinguished Lecture on Bench-to-Bedside New Drugs & New Targets
How Prostate Cancers Escape ARSI Therapy Through Lineage Transition****Charles Sawyers, MD**

Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute

Introduced by Elizabeth Wasmuth, PhD · UT Health San Antonio; Howard Hughes Medical Institute

1:55 PM - 2:00 PM Discussion**SPEAKER BIOGRAPHY**

Charles Sawyers is a Howard Hughes Medical Institute Investigator and Chair of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center. He co-discovered the antiandrogen drug enzalutamide, approved by the FDA in 2012 for treatment of advanced prostate cancer. He received the Lasker-DeBakey Clinical Medical Research Award for development of ABL kinase inhibitors for chronic myeloid leukemia and the Breakthrough Prize in Life Sciences. Sawyers is a member of the National Academy of Sciences and National Academy of Medicine.

2:00 PM - 2:15 PM**PRAC1: A New Target for AR-Driven Prostate Cancer**

Elizabeth Wasmuth, PhD · UT Health San Antonio; Howard Hughes Medical Institute

Michael Haffner, MD, PhD · Fred Hutchinson Cancer Center

2:15 PM - 2:20 PM

Discussion**2:20 PM - 2:35 PM****JNJ-6143 (Formerly HLD-0915): A First-in-Class Oral AR-BRD4 RIPTAC™ Molecule for the Treatment of Prostate Cancer**

Kat Kayser-Bricker, PhD · Johnson & Johnson Innovative Medicine

2:35 PM - 2:40 PM

Discussion**SPECIAL LECTURE**

2:40 PM - 2:55 PM

Reimagining the CRO: From Vendor to Scientific Partner**Paul VanVeldhuisen, PhD**

Emmes

Introduced by Phillip Koo, MD | Prostate Cancer Foundation

2:55 PM - 3:00 PM Discussion**SPEAKER BIOGRAPHY**

Dr. Paul VanVeldhuisen is Chief Scientific Officer and President of Emmes Public Sector at The Emmes Company, a clinical research organization he has been with since 1993. He holds a PhD in Epidemiology from George Washington University and an MS in Biostatistics from the University of Washington. He has led statistical and data coordinating centers for numerous NIH-sponsored multicenter clinical trials, has served on several Data and Safety Monitoring Boards, and has authored more than 100 peer-reviewed publications.

SESSION 6

3:00 PM - 4:10 PM

Lessons and Next Steps in the Neoadjuvant Space

Moderator: Rana McKay, MD | University of California, San Diego

3:00 PM - 3:05 PM

Introduction**3:05 PM - 3:20 PM****Immunotherapy in the Neoadjuvant Space**

Sumit Subudhi, MD, PhD · University of Texas MD Anderson Cancer Center

3:20 PM - 3:25 PM

Discussion**3:25 PM - 3:45 PM****Genomic Alterations and Pathologic Responses to Neoadjuvant Androgen Receptor Pathway Inhibitor (ARPI) Doublets vs Triplets in the Genomic Umbrella Neoadjuvant Study (GUNS)**

Martin Gleave, MD · University of British Columbia

3:45 PM - 3:50 PM

Discussion

SESSION 6 · Lessons and Next Steps in the Neoadjuvant Space (continued)

3:50 PM - 4:05 PM	Insights from PROTEUS: Clinical Trial Endpoints in Neoadjuvant Therapy Mary-Ellen Taplin, MD · Dana-Farber Cancer Institute; Harvard Medical School
4:05 PM - 4:10 PM	<i>Discussion</i>

PANEL DISCUSSION

4:10 PM - 5:00 PM

New Endpoints and Implications for Prostate Cancer Clinical Trials

Moderator: Fatima Karzai, MD | National Cancer Institute
Panelists: Mary-Ellen Taplin, MD (Dana-Farber Cancer Institute; Harvard Medical School) · Susan Halabi, PhD (Duke University) · Praful Ravi, MD (Dana-Farber Cancer Institute) · Max Loda, MD (Weill Cornell Medicine) · Rana McKay, MD (University of California, San Diego) · Martin Gleave, MD (University of British Columbia)

5:00 PM - 6:30 PM	Break	
6:30 PM - 7:00 PM	Reception	Costa Del Sol Foyer

Dinner & Awards Ceremony Costa Del Sol Ballroom	7:00 PM - 9:30 PM
Welcome Remarks Gina Carithers · Prostate Cancer Foundation Phillip Koo, MD · Prostate Cancer Foundation	7:10 PM - 7:15 PM
Tribute to Dr. Howard Soule Andrea Miyahira, PhD · Prostate Cancer Foundation Joshua Lang, MD · University of Wisconsin Himisha Beltran, MD · Dana-Farber Cancer Institute	7:15 PM - 7:25 PM
PCF Awards Ceremony 2026 PCF Young Investigator Awards 2026 Felix Feng ASCO Young Investigator Award 2026 HBCU-PCF Recognition Award 2026 PCF Challenge Awards 2025 PCF Challenge Awards 2025 PCF TACTICAL Award	7:45 PM - 9:00 PM

DAY THREE

Sunday

October 4, 2026

AT A GLANCE

General Sessions · Costa Del Sol Ballroom

7:00 AM - 7:45 AM	Breakfast Costa Del Sol Patio & Costa Del Sol Ballroom
7:15 AM - 8:00 AM	Sponsored Breakfast Presentation Amgen
8:00 AM - 8:20 AM	Session 7: Panel Discussion: Community Clinical Research
8:20 AM - 9:50 AM	Session 8: Advances in Prostate Cancer Precision Medicine
9:50 AM - 10:55 AM	Session 9: Agentic AI for Biology Discovery
10:55 AM - 12:15 PM	Session 10: Theranostics
12:15 PM - 12:20 PM	Closing Remarks
12:20 PM	Meeting Adjourned Box Lunch Provided

LOCATIONS

Costa Del Sol Ballroom

General Sessions & Sponsored Presentations

Costa Del Sol Patio

Breakfast, Lunch & Friday Dinner

Costa Del Sol Foyer

Registration & Group Photo

Costa De La Luna Ballroom

Poster Session & Dessert

7:00 AM - 7:45 AM

Breakfast

Costa Del Sol Patio & Costa Del Sol Ballroom

SPONSORED BREAKFAST PRESENTATION · COSTA DEL SOL BALLROOM

7:15 AM - 8:00 AM

TBD

TBD · Amgen

SESSION 7

8:00 AM - 8:20 AM

Community Clinical Research

Moderator: Phillip Koo, MD | Prostate Cancer Foundation

Panelists: Paul VanVeldhuisen, PhD (Emmes) · Leanne Woods-Burnham, PhD (Morehouse School of Medicine) · Steven Finkelstein, MD (Associated Medical Professionals / US Urology Partners)

SESSION 8

8:20 AM - 9:50 AM

Advances in Prostate Cancer Precision Medicine

Moderator: Steven Kregel, PhD | Loyola University Chicago

8:20 AM - 8:25 AM

Introduction

DISTINGUISHED LECTURE

8:25 AM - 8:45 AM

Arul Chinnaiyan Distinguished Lecture on Advances in Prostate Cancer Precision Medicine

Beyond Inhibition: Heterobifunctional Molecules and the Future of Prostate Cancer Therapy

Arul Chinnaiyan, MD, PhD

University of Michigan

Introduced by Steven Kregel, PhD | Loyola University Chicago

8:45 AM - 8:50 AM Discussion



SPEAKER BIOGRAPHY

Arul M. Chinnaiyan directs the Michigan Center for Translational Pathology at the University of Michigan and is an HHMI Investigator. His landmark discovery of TMPRSS2-ETS gene fusions transformed our understanding of prostate cancer and informed the development of the MyProstateScore 2.0 urine test. A pioneer in precision oncology, he established the Mi-Oncoseq clinical sequencing program and is now developing heterobifunctional therapeutics, including DALTACs, that target and reprogram cancer-driving protein complexes to enable more precise and effective prostate cancer treatment.

8:50 AM - 9:05 AM

The War of Warheads: Optimizing and Multiplexing Cytotoxic Payloads in ADC Design for mCRPC

Galina Semenova, MD, PhD · University of California, Los Angeles

9:05 AM - 9:10 AM

Discussion

9:10 AM - 9:25 AM

First-in-Human Assessment of Actinium-225-Prostate-Specific Membrane Antigen (²²⁵Ac-PSMA)-Trillium (BAY 3563254) in mCRPC: Dose-Escalation Results of the Phase 1 PANTHA Study

Sebastien Hotte, MD · McMaster University

9:25 AM - 9:30 AM

Discussion

9:30 AM - 9:45 AM

Updates on Lessons and Outcomes from TALAPRO-3

Neeraj Agarwal, MD · Dana-Farber Cancer Institute

9:45 AM - 9:50 AM

Discussion

SESSION 9

9:50 AM - 10:55 AM

Agentic AI for Biology Discovery

Moderator: Eliezer Van Allen, MD | Dana-Farber Cancer Institute

9:50 AM - 9:55 AM

Introduction

9:55 AM - 10:10 AM

Evaluating Agentic AI for Prostate Cancer Precision Medicine

Eliezer Van Allen, MD · Dana-Farber Cancer Institute

10:10 AM - 10:15 AM

Discussion

10:15 AM - 10:30 AM

Agentic AI for Biology Discovery

Marinka Zitnik, PhD · Harvard Medical School

10:30 AM - 10:35 AM

Discussion

SESSION 9 · Agentic AI for Biology Discovery (continued)

10:35 AM - 10:50 AM	Automating Science Research Jeff Leek, PhD · Fred Hutchinson Cancer Center
10:50 AM - 10:55 AM	<i>Discussion</i>

SESSION 10

10:55 AM - 12:15 PM

Theranostics 2026: New Signals, New Sequences

Moderator: Louise Emmett, MD | St. Vincent's Hospital Sydney

10:55 AM - 11:00 AM	<i>Introduction</i>
11:00 AM - 11:15 AM	Prognostic and Predictive Biomarkers within the ENZA^p Trial Louise Emmett, MD · St. Vincent's Hospital Sydney Sofie Tolmeijer, PhD · Vancouver Prostate Centre, University of British Columbia
11:15 AM - 11:20 AM	<i>Discussion</i>
11:20 AM - 11:35 AM	The Evolving Technology of Total Body PET - 50 Years of PET and Still Going Michael Hofman, MBBS · Peter MacCallum Cancer Centre
11:35 AM - 11:40 AM	<i>Discussion</i>
11:40 AM - 11:55 AM	CONV01-Alpha, an Actinium-Conjugated Radioantibody: Current Progress and Future Directions Jones Nauseef, MD, PhD · Convergent
11:55 AM - 12:00 PM	<i>Discussion</i>
12:00 PM - 12:10 PM	PSMAddition: Phase 3 trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer Michael Morris, MD · Memorial Sloan Kettering Cancer Center
12:10 PM - 12:15 PM	<i>Discussion</i>
12:15 PM - 12:20 PM	Closing Remarks Andrea Miyahira, PhD · Prostate Cancer Foundation Phillip Koo, MD · Prostate Cancer Foundation
12:20 PM	Meeting Adjourned Box Lunch Provided

Program Committee

CO-CHAIRS

Andrea Miyahira, PhD

Phillip Koo, MD

Gina Carithers

Prostate Cancer Foundation

Prostate Cancer Foundation

Prostate Cancer Foundation

COMMITTEE MEMBERS

Louise Emmett, MD

Cory Abate-Shen, PhD

Yu Chen, MD, PhD

Fatima Karzai, MD

Susan Halabi, PhD

Eliezer Van Allen, MD

St. Vincent's Hospital Sydney

Columbia University

Memorial Sloan Kettering Cancer Center

National Cancer Institute

Duke University

Dana-Farber Cancer Institute



Retreat Supporters

We deeply thank our Retreat supporters for providing funding for this educational initiative.

Platinum

Johnson & Johnson

Gold

AMGEN®



Pfizer

Silver

astellas



AstraZeneca

NOVARTIS

Daiichi-Sankyo

REGENERON
SCIENCE TO MEDICINE®

Bronze

abbvie

AdvanCell

Bristol Myers Squibb™



CANDEL
THERAPEUTICS

FOUNDATION
MEDICINE®

LANTHEUS

SUN
PHARMA

MERCK
Rahway, NJ, USA

RayzeBio®
A Bristol Myers Squibb Company

Telix

veracyte. | Decipher.

CLARITY
PHARMACEUTICALS

Convergent™
THERAPEUTICS

FLARE
THERAPEUTICS

CURIUM
LIFE FORWARD

syncromune
SYNCHRONIZING THE POWER OF IMMUNOTHERAPY

PROSTATE CANCER FOUNDATION
PCF
CURING TOGETHER